News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,740 Results
Type
Article (13568)
Company Profile (110)
Press Release (247062)
Section
Business (87936)
Career Advice (461)
Deals (15325)
Drug Delivery (63)
Drug Development (36525)
Employer Resources (49)
FDA (6259)
Job Trends (6182)
News (150011)
Policy (14006)
Tag
Academia (435)
Alliances (23074)
Alzheimer's disease (347)
Approvals (6250)
Artificial intelligence (58)
Bankruptcy (143)
Best Places to Work (4307)
Biosimilars (39)
Biotechnology (44)
Breast cancer (38)
Cancer (284)
Career advice (405)
Cell therapy (39)
Clinical research (30327)
Collaboration (129)
Compensation (55)
COVID-19 (746)
C-suite (49)
Data (290)
Diabetes (47)
Diagnostics (1230)
Drug pricing (56)
Earnings (31445)
Employer resources (43)
Events (36634)
Executive appointments (145)
FDA (6422)
Funding (91)
Gene therapy (58)
GLP-1 (287)
Government (1264)
Healthcare (3517)
Infectious disease (763)
Inflammatory bowel disease (45)
Interviews (58)
IPO (5809)
Job creations (2049)
Job search strategy (372)
Layoffs (166)
Legal (3409)
Lung cancer (44)
Manufacturing (85)
Medical device (1260)
Medtech (1262)
Mergers & acquisitions (9535)
Metabolic disorders (154)
Neuroscience (436)
NextGen Class of 2024 (1580)
Non-profit (589)
Northern California (388)
Obesity (96)
Opinion (108)
Patents (51)
People (28405)
Pharmaceutical (64)
Phase I (7884)
Phase II (12825)
Phase III (11527)
Pipeline (134)
Podcasts (39)
Policy (43)
Postmarket research (1399)
Preclinical (3161)
Radiopharmaceuticals (116)
Rare diseases (82)
Real estate (2629)
Regulatory (9801)
Research institute (562)
Resumes & cover letters (55)
Southern California (398)
Startups (1624)
United States (3902)
Vaccines (109)
Weight loss (76)
Date
Today (71)
Last 7 days (333)
Last 30 days (1076)
Last 365 days (12718)
2024 (11095)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14887)
2018 (11713)
2017 (13890)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10889)
Location
Africa (312)
Arizona (39)
Asia (19753)
Australia (2552)
California (907)
Canada (559)
China (100)
Connecticut (37)
Europe (38699)
Florida (130)
Illinois (102)
Indiana (81)
Kansas (51)
Maryland (146)
Massachusetts (801)
Minnesota (50)
New Jersey (384)
New York (250)
North Carolina (269)
Northern California (388)
Pennsylvania (265)
South America (498)
Southern California (398)
Texas (121)
Virginia (37)
Washington State (66)
260,740 Results for "galmed pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
April 4, 2024
·
5 min read
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”) announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.
March 15, 2024
·
6 min read
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.
November 20, 2023
·
5 min read
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Galmed Pharmaceuticals Ltd. announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.
September 26, 2023
·
6 min read
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
Galmed Pharmaceuticals Ltd. reported the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M.
May 4, 2023
·
7 min read
Business
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments
June 1, 2023
·
8 min read
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - September 22, 2023
Galmed Pharmaceuticals Ltd. announced that the Company received a letter from the Nasdaq Listing Qualifications, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.
September 22, 2023
·
5 min read
Deals
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Galmed Pharmaceuticals Ltd. announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the “Offering”).
July 14, 2023
·
6 min read
Business
Galmed to employ OnKai’s disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
Galmed Pharmaceuticals Ltd. is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed’s innovative Primary Sclerosing Cholangitis (PSC) clinical development program.
July 10, 2023
·
6 min read
Business
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission.
March 29, 2023
·
4 min read
1 of 26,074
Next